N@N

CTD Holdings, Inc. Signs Letter of Intent With J. Jireh Holdings, LLC

_{//health-fitness.news-articles.net/content/2009/ .. -letter-of-intent-with-j-jireh-holdings-llc.html}
^{Published in Health and Fitness on Tuesday, December 22nd 2009 at 5:10 GMT by Market Wire}  

HIGH SPRINGS, FL--(Marketwire - December 22, 2009) - CTD Holdings, Inc. (OTCBB: [ CTDH ]) (FRANKFURT: CDJ) announced today that the Company has entered into a Letter of Intent to form a Joint Venture with J. Jireh Holdings, LLC.

Under the agreement CTD Holdings will contribute cash and other assets to a joint venture (JV) with J. Jireh which will contribute know how and other assets. The JV will develop and manufacture proprietary cyclodextrin complexes and branded products utilizing joint intellectual contributions and the pulse combustion dryer purchased by the JV. The physical plant is located and operating in Payson, Arizona.

"This joint venture will combine over $1.0 million dollars of intellectual, physical and cash assets to develop and manufacture branded cyclodextrin complexes and products," stated C.E. "Rick" Strattan, Chief Executive Officer of CTD Holdings, Inc. Mr. Strattan further stated, "We believe that by combining pulse combustion drying techniques unique to J. Jireh, the CD innovations of CTD and the pulse drying expertise of Dr. Jeff Tate, the new joint venture, to be called NanoSonic, Products, Inc., will quickly develop products enhanced by complexation with the right CD. Our first products will focus on the nutraceutical and alternative energy industries."

Jeffrey Tate PhD, will join the JV as Chief Operating Officer and President. Mr. Strattan will be the Chief Executive Officer of the JV.

ViStra Growth Partners, Inc., a wholly owned subsidiary of CTD Holdings, was an integral part of the corporate structure, negotiating and assembly of the documents necessary to affect the Letter of Intent. Mr. Louis Weltman, CEO of ViStra stated, "We are confident that our contribution to this strategic alliance will assist CTD in its efforts to more fully develop its potential as an innovator, manufacturer and developer of cyclodextrin complexes."

About CTD Holdings, Inc.

The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann Pick C disease, a debilitating childhood disease often called Childhood Alzheimer's. More information about the company is available on the company's website: [ www.cyclodex.com ]

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.